HA Injection Safety: 25+ Years of FDA Post-Market Data
FDA-approved since 1997, HA injections have an extensive safety record. Review 25+ years of adverse event data, MAUDE database findings, and why HA is considered very low-risk.
By Joint Pain Authority Team
Key Safety Findings
Over 25 years of FDA post-market surveillance demonstrate an excellent safety profile:
- FDA approved since 1997 - Synvisc was first; multiple products followed
- Millions of injections administered in the US
- MAUDE database: Low adverse event reporting rate
- No systemic toxicity - HA is a natural body substance
- No cumulative damage - Safe for repeat courses
- Local reactions only - Most side effects are injection-site related
- Rare serious events - Much lower risk than NSAIDs or surgery
The FDA Approval History
Timeline of US Approvals
Hyaluronic acid products for knee OA have been FDA-approved for over 25 years:[1]
FDA Approval Timeline:
| Year | Product | Manufacturer | Source |
|---|---|---|---|
| 1997 | Synvisc | Sanofi | Avian (rooster comb) |
| 1997 | Hyalgan | Fidia | Avian |
| 2001 | Supartz | Bioventus | Avian |
| 2004 | Orthovisc | Anika | Avian |
| 2004 | Euflexxa | Ferring | Bacterial fermentation |
| 2009 | Synvisc-One | Sanofi | Avian |
| 2011 | Gel-One | Zimmer | Avian |
| 2012 | Monovisc | Anika | Avian |
| 2017 | Durolane | Bioventus | Bacterial fermentation |
| 2023 | Visco-3 | Anika | Avian |
What FDA Approval Means
The MAUDE Database: Post-Market Safety
What Is MAUDE?
The Manufacturer and User Facility Device Experience (MAUDE) database is the FDA’s system for collecting adverse event reports for medical devices:[2]
- Mandatory reporting by manufacturers
- Voluntary reporting by healthcare providers and patients
- Publicly searchable
- Updated regularly
MAUDE Data for HA Injections
Adverse Event Analysis (Representative Period):
| Category | Finding |
|---|---|
| Total reports (2014-2019) | ~63 reports across all HA products |
| Reporting rate | Very low relative to millions of procedures |
| Serious outcomes | Rare; most reports describe local reactions |
| Deaths reported | 8 (causality unconfirmed; often comorbidities) |
Note: MAUDE captures reported events; actual causality often undetermined.
Context for MAUDE Numbers
Types of Adverse Events
Common (Expected) Side Effects
These occur in some patients and are not considered serious:[3]
Local Injection-Site Reactions:
| Reaction | Frequency | Duration |
|---|---|---|
| Pain at injection site | 10-20% | Hours to 1-2 days |
| Swelling | 5-10% | 1-3 days |
| Warmth/redness | 5-10% | 1-2 days |
| Stiffness | 5-15% | 1-2 days |
These are self-limiting and typically resolve without treatment.
Uncommon Side Effects
Rare Serious Events
Very Rare Events (MAUDE reports):
| Event | Context |
|---|---|
| Infection | Any injection carries small infection risk |
| Severe allergic reaction | Extremely rare; managed with standard allergy protocols |
| Deaths reported | 8 reports (2014-2019); causality not established; patients had comorbidities |
Important: The presence of a MAUDE report does not prove the product caused the event. Many reports involve patients with multiple health conditions where causality cannot be determined.
Comparison to Other OA Treatments
Safety Profile Comparison
Relative Safety of OA Treatments:
| Treatment | Major Safety Concerns | Risk Level |
|---|---|---|
| HA injections | Local reactions; rare allergic response | Very Low |
| Acetaminophen | Liver toxicity at high doses | Low-Moderate |
| NSAIDs (oral) | GI bleeding (1-2%/yr in 65+); CV risk (25% increase); renal effects | Moderate-High |
| Cortisone injections | Cartilage damage; blood sugar spikes; limited frequency | Moderate |
| Opioids | Addiction; constipation; falls; cognitive effects | High |
| Knee replacement | Surgical risks; revision risk; anesthesia; DVT/PE | Higher (for surgery) |
The NSAID Comparison
NSAIDs are often the default OA treatment, but chronic use carries significant risks:
HA injections avoid all of these systemic risks because they work locally in the joint.
Why HA Is Inherently Safe
HA Is Natural
Hyaluronic acid is a naturally occurring substance in the body:
Local Administration
Unlike oral medications, HA stays in the joint:
No Cumulative Effects
Avian vs. Non-Avian Safety
The Allergy Question
Some HA products are derived from rooster combs (avian source), raising allergy concerns for some patients:
Product Sources:
| Product | Source | Allergy Consideration |
|---|---|---|
| Synvisc, Synvisc-One | Avian | Caution with egg/poultry allergy |
| Hyalgan | Avian | Caution with egg/poultry allergy |
| Supartz | Avian | Caution with egg/poultry allergy |
| Orthovisc | Avian | Caution with egg/poultry allergy |
| Euflexxa | Bacterial fermentation | Safe for egg/poultry allergies |
| Durolane | Bacterial fermentation | Safe for egg/poultry allergies |
Safety for Allergic Patients
Contraindications and Precautions
Who Should Not Receive HA
Contraindications:
| Situation | Reason |
|---|---|
| Active knee infection | Risk of worsening infection |
| Skin infection at injection site | Risk of introducing bacteria |
| Known HA allergy | Prior allergic reaction to HA products |
| Egg/poultry allergy | Use non-avian product (Euflexxa, Durolane) |
Precautions
Long-Term Safety Evidence
What 25+ Years Tells Us
Ongoing Surveillance
FDA continues to monitor HA products through:
- MAUDE database adverse event reports
- Post-marketing study requirements
- Annual manufacturer reports
- Periodic safety reviews
The Bottom Line
25+ Years of Safety Data
The evidence is clear:
- FDA-approved since 1997 with continuous market presence
- Millions of injections with very low adverse event rate
- No systemic toxicity - HA is a natural body substance
- No cumulative damage - safe for long-term repeated use
- Much safer than NSAIDs - avoids CV, GI, and renal risks
- Local reactions only - mild and self-limiting when they occur
- Rare serious events - lower risk than most OA treatment alternatives
What this means for you:
HA injections have one of the best safety profiles of any OA treatment. With over 25 years of post-market surveillance confirming their safety, concerns about HA being “experimental” or “risky” are not supported by the evidence.
If you’re considering HA injections, the safety data should provide reassurance. The main questions are efficacy for your specific situation—not safety.
Frequently Asked Questions
How long have HA injections been FDA-approved?
Hyaluronic acid injections have been FDA-approved for knee osteoarthritis since 1997, when Synvisc and Hyalgan received approval. Over 25 years of post-market surveillance have confirmed their excellent safety profile, with no new safety signals, no black box warnings added, and no product withdrawals for safety reasons.
What are the side effects of HA knee injections?
The most common side effects are mild, temporary injection-site reactions including pain (10-20%), swelling (5-10%), warmth or redness (5-10%), and stiffness (5-15%). These typically resolve within 1 to 3 days without treatment. Serious adverse events are extremely rare.
Are HA injections safer than taking ibuprofen every day?
Yes. Unlike chronic NSAID use, which increases cardiovascular risk by 25%, causes GI bleeding in 1-2% of seniors annually, and can damage kidneys, HA injections work locally in the joint with no systemic side effects, no drug interactions, and no cumulative toxicity.
Can I get HA injections if I have an egg allergy?
Yes. Non-avian HA products like Euflexxa and Durolane are made from bacterial fermentation rather than rooster combs, making them safe for patients with egg or poultry allergies. Always inform your provider of any allergies before treatment.
Can HA injections be repeated safely over many years?
Yes. Unlike cortisone injections, which can damage cartilage with repeated use, HA injections show no evidence of cumulative joint damage. Patients have safely used HA for 10 or more years, with repeat courses every 6 months as needed.
Find Safe, Evidence-Based Treatment
Locate providers who offer FDA-approved HA products with proper technique.
Your information is secure. See our Privacy Policy and Terms of Service.
Thank You!
We've received your request. A provider specialist will contact you within 1-2 business days to help you find the right care.
What happens next?
- 1 We'll verify your insurance coverage
- 2 Match you with quality providers in your area
- 3 Contact you to discuss your options
Questions? Browse our guides:
How to Choose a ProviderReferences
-
FDA Premarket Approval Database. Device Approvals for Viscosupplementation Products. FDA
-
FDA MAUDE Database. Adverse Event Reports for Viscosupplementation Devices. FDA MAUDE
-
Synvisc-One Prescribing Information. Sanofi. FDA Label
-
Euflexxa Prescribing Information. Ferring Pharmaceuticals.
-
Comprehensive review of viscosupplementation safety. Orthopedic Reviews. Full Text
Safety Updates
Stay informed about the latest safety data for joint pain treatments.
Join 10,000+ readers. No spam.
Related Resources
Topics
Enjoyed this article?
Get more insights like this delivered to your inbox weekly.
Join 10,000+ readers. No spam.